{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:51:49Z","timestamp":1761663109931},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,10,4]],"date-time":"2012-10-04T00:00:00Z","timestamp":1349308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Autoantibodies in hepatitis C virus\u2013infected patients may indicate autoimmune hepatitis or other immune\u2010mediated diseases. This may impact safety and efficacy of interferon\u2010based therapy of chronic hepatitis C. We investigated the association between a positive test result for a variety of autoantibodies and the initiation and efficacy of therapy for chronic hepatitis C. We analysed an observational cohort of 24\u00a0306 patients for an association between autoantibodies and treatment outcome. 8241 patients were tested simultaneously for antinuclear antibodies (<jats:styled-content style=\"fixed-case\">ANA<\/jats:styled-content>), liver kidney microsomal antibodies (<jats:styled-content style=\"fixed-case\">LKM<\/jats:styled-content>), smooth muscle antibodies (<jats:styled-content style=\"fixed-case\">SMA<\/jats:styled-content>) and antimitochondrial antibodies (<jats:styled-content style=\"fixed-case\">AMA<\/jats:styled-content>). Matched\u2010pair analysis was performed matching one autoantibody\u2010positive patient to three controls. Control patients had negative tests for all four antibodies. Analyses were performed for patients with a single positive autoantibody test and for patients with multiple positive autoantibody tests. A positive test result for <jats:styled-content style=\"fixed-case\">ANA<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> LKM<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> SMA<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">AMA<\/jats:styled-content> did not affect the physician's decision to initiate therapy with pegylated interferon and ribavirin. In addition, a positive test for one or multiple autoantibodies did not adversely affect sustained virologic response. There was no difference in fibrosis stage or alanine transaminase at baseline or during therapy irrespective of antibody status. Thyroid dysfunction was more frequent in patients with positive <jats:styled-content style=\"fixed-case\">LKM<\/jats:styled-content> antibodies (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.004). Initiation of therapy for chronic hepatitis C and outcome were not affected by the presence of <jats:styled-content style=\"fixed-case\">ANA<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> LKM<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> SMA<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">AMA<\/jats:styled-content>. Routine testing of these autoantibodies seems not warranted. Determination of autoantibodies should be guided by individualized clinical decisions.<\/jats:p>","DOI":"10.1111\/jvh.12011","type":"journal-article","created":{"date-parts":[[2012,10,5]],"date-time":"2012-10-05T03:29:23Z","timestamp":1349407763000},"source":"Crossref","is-referenced-by-count":19,"title":["Screening for autoantibodies in chronic hepatitis <scp>C<\/scp> patients has no effect on treatment initiation or outcome"],"prefix":"10.1111","volume":"20","author":[{"given":"S.","family":"Mauss","sequence":"first","affiliation":[{"name":"Center for HIV and Hepatogastroenterology Dusseldorf Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Berger","sequence":"additional","affiliation":[{"name":"Center for HIV and Hepatogastroenterology Dusseldorf Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schober","sequence":"additional","affiliation":[{"name":"Center for Gastroenterology G\u00f6ttingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Moog","sequence":"additional","affiliation":[{"name":"Center for Gastroenterology Kassel Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Heyne","sequence":"additional","affiliation":[{"name":"Center for Gastroenterology and Liver Center Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"John","sequence":"additional","affiliation":[{"name":"Center for Gastroenterology Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Pape","sequence":"additional","affiliation":[{"name":"Center for Gastroenterology Paderborn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Hueppe","sequence":"additional","affiliation":[{"name":"Center for Gastroenterology Herne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Pfeiffer\u2010Vornkahl","sequence":"additional","affiliation":[{"name":"Factum \u2013 company for statistics, scientific information and communication mbH Offenbach Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Alshuth","sequence":"additional","affiliation":[{"name":"BU Virology Roche Pharma AG Grenzach\u2010Wyhlen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,10,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-4-4"},{"key":"e_1_2_7_3_1","first-page":"168","article-title":"Response to treatment with interferon\u2010alfa in patients with chronic hepatitis C and high titers of \u2010M2, \u2010M4 and \u2010M8 antimitochondrial antibodies","volume":"91","author":"Garrido Palma G","year":"1999","journal-title":"Rev Esp Enferm Dig"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2004.00530.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e3283089392"},{"key":"e_1_2_7_6_1","first-page":"258","article-title":"Prevalence and clinical relevance of serum autoantibodies in patients with chronic hepatitis C","volume":"33","author":"Chen CH","year":"2010","journal-title":"Chang Gung Med J"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.01035.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/427285"},{"key":"e_1_2_7_9_1","first-page":"5","article-title":"Prevalence of antinuclear and anti\u2010liver\u2010kidney\u2010microsome type\u20101 antibodies in patients with chronic hepatitis C in China","volume":"122","author":"Bai L","year":"2009","journal-title":"Chin Med J (Engl)"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.02.020"},{"key":"e_1_2_7_11_1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1177\/135965350501000610","article-title":"The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver\u2010kidney microsome type 1 antibodies","volume":"10","author":"Monti V","year":"2005","journal-title":"Antivir Ther"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(98)80344-9"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260305"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840220506"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1110008"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80372-9"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12011","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12011","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T01:26:49Z","timestamp":1698629209000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,4]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1111\/jvh.12011"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12011","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,4]]}}}